Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q4 2023 Earnings Report

Pharvaris logo
$29.68 -0.43 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$29.62 -0.05 (-0.19%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.56
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q4 2023
Date
5/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pharvaris' Q2 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris' Q4 2023 Press ReleasePress Release
(8-K)
Pharvaris' Q4 2023 Annual ReportAnnual Report
(20-F)

Pharvaris Earnings Headlines

Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock
May 4 at 5:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30757899
Pharvaris (NASDAQ:PHVS) Insider Sells $111,296.00 in Stock
May 4 at 5:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30757901
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 7 at 1:00 AM  |  American Alternative (Ad)
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
April 30, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/04/29/for-pharvaris-investors-the-director-s-sale-matters-less-than-what-s-coming-next/
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276834/0/en/Evidence-Supporting-Combined-Use-of-Deucrictibant-IR-with-Deucrictibant-XR-Presented-at-CIIC-Spring-2026-Conference.html
Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 Conference - Slideshow
April 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891541-pharvaris-n-v-phvs-presents-at-ciic-spring-2026-conference-slideshow
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

View Pharvaris Profile
Earnings Tools